Novo Nordisk A/S (NYSE:NVO) reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli Lilly and Co. (NYSE:LLY).

Martin Holst Lange, chief scientific officer at Novo Nordisk, confirmed the company's intentions Tuesday during the European Association for the Study of Diabetes conference in Vienna. Although the company has not yet formally announced its plans, it is preparing to submit an application to the U.S. Food and Drug Administration (FDA) for approval.

Also Read: Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

High-dose Wegovy offers the same weight-loss potential as Lilly's Zepbound, giving patients another option, Lange told Bloomberg in an interview.

"Obviously, our competitors have optimized the dosing," ...